Dr. Berg discusses unmet needs in metastatic urothelial cancer
“I think really identifying who's going to benefit from what combination for how long is going to be important,” says Stephanie Berg, DO.
In this video, Stephanie Berg, DO, an instructor of medicine at Harvard Medical School, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, discusses unmet needs in the metastatic bladder cancer paradigm. There have been tremendous breakthroughs in this space with treatments such as immunotherapies, antibody-drug conjugates, and targeted agents. However, as Berg explains, a complete precision medicine approach–whereby the right patient receives the right treatment at the right time—remains an elusive goal. Berg is an instructor of medicine, Harvard Medical School, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute.
Transcript
I think it's really identifying the proper patient to receive which therapy because safety, as I mentioned, is really important. And these drugs can have lots of long-lasting side effects. So I think really identifying who's going to benefit from what combination for how long is going to be important. For example, with dosing—do they need x number of cycles? Does the patient need a lower dose? Would the lower dose have the same efficacy? So, I think, once we establish, perhaps, the best regimen from these trials, looking how to de-escalate for patients who have incurable disease so they can have a better quality of life I think will be really interesting to explore in the future.
The transcript has been edited for clarity.
Cell therapy TARA-002 shows initial promise in NMIBC
April 9th 2024"This encouraging anti-tumor activity coupled with a favorable safety profile and mode of administration that is both convenient and familiar to urologists indicates that, if confirmed in future studies, TARA-002 could potentially play a meaningful role in NMIBC treatment in the future," says Timothy D. Lyon, MD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.
